

Table 9.6i
Immunosuppression Use for Antirejection Treatment from Transplant
to One Year Following Transplantation, 1997 to 2006
Recipients with Liver Transplants

	Year of Transplant									
	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006
Transplants	4,188	4,516	4,751	4,997	5,195	5,332	5,673	6,170	6,443	6,650
Tx with Antirejection Treatments	1,324	1,184	1,466	1,499	1,417	1,301	1,041	994	1,036	822
Antibodies										
Any in Category	12.1%	13.1%	12.5%	14.5%	16.7%	17.5%	17.8%	21.2%	14.9%	15.1%
Atgam/NRATG/NRATS	1.4%	1.4%	0.7%	0.5%	0.5%	0.6%	0.8%	0.8%	1.1%	0.5%
OKT3	11.1%	9.7%	6.8%	6.3%	6.7%	5.9%	5.4%	5.7%	4.5%	3.6%
Thymoglobulin	0.0%	0.3%	1.4%	3.2%	5.2%	5.6%	7.0%	11.3%	7.5%	8.9%
Zenapax	0.2%	0.9%	1.7%	2.4%	1.6%	1.9%	1.3%	3.4%	0.8%	0.9%
Simulect	0.1%	1.2%	3.1%	3.1%	4.2%	4.0%	3.0%	0.8%	0.9%	0.6%
Campath	0.0%	0.0%	0.0%	0.0%	0.0%	0.6%	2.0%	1.4%	1.0%	1.3%
Corticosteroids										
Any in Category	84.1%	87.3%	89.5%	90.7%	89.1%	90.3%	91.6%	88.5%	91.5%	92.2%
Steroids	84.1%	87.3%	89.5%	90.7%	89.1%	90.3%	91.6%	88.5%	91.5%	92.2%
Antimetabolites										
Any in Category	0.7%	0.3%	0.2%	0.1%	0.1%	0.0%	0.1%	0.0%	0.3%	0.1%
Cytosan	0.7%	0.3%	0.2%	0.1%	0.1%	0.0%	0.1%	0.0%	0.2%	0.1%
Methotrexate	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.1%	0.0%

Source: OPTN/SRTR Data as of May 1, 2008.

Notes:

Individual drug percentages will not necessarily add up to the drug category percentages, as patients may be prescribed more than one drug within the same category.